SCHEMBL10243666

SCHEMBL10243666

COC(=O)NCCNC(C)c1ccnn1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
ITGA4 P13612 1/20 0.33
ITGB7 P26010 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33
ATM Q13315 1/20 0.33
TSHR P16473 1/20 0.33
CTSK P43235 1/20 0.32
KCNA5 P22460 1/20 0.32
MC4R P32245 1/20 0.32
GPR52 Q9Y2T5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244130 0.84 RAB9A (0.38) KMT2AL3MBTL1GAATP53ALDH1A1
SCHEMBL10243738 0.77 SMN1; SMN2 (0.35) KMT2AGAATP53POLBKDM4E
SCHEMBL10243520 0.77 RAB9A (0.38) KMT2AGAATP53POLBALDH1A1
SCHEMBL334651 0.76 CYP3A4 (0.33) KMT2AL3MBTL1POLBALDH1A1HTT
SCHEMBL10243567 0.76 TAS1R3 (0.34) KMT2AL3MBTL1TAS1R3TAS1R1TAS1R2
SCHEMBL10244577 0.73 RAB9A (0.38) KMT2AL3MBTL1TP53ALDH1A1HSD17B10
SCHEMBL12473308 0.73 SIGMAR1 (0.35) KMT2AL3MBTL1GAAPOLB
SCHEMBL10244071 0.71 TSHR (0.36) KMT2AKDM4EALDH1A1HSD17B10HTT
SCHEMBL10244285 0.70 ESR1 (0.42) ALDH1A1HTT
SCHEMBL10244889 0.69 CA12 (0.40) TAS1R3TAS1R1TAS1R2TSHRKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KMT2A 939/4885L3MBTL1 2853/4885TAS1R3 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.